Loading...
Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors
BACKGROUND: cKIT kinase overexpression and gain-of-function mutations are the critical pathogenesis of gastrointestinal stromal tumors (GISTs). Although the multiple kinase inhibitors such as imatinib, sunitinib, and regorafenib have been approved for GISTs, the acquisition of polyclonal secondary r...
Na minha lista:
| Udgivet i: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535728/ https://ncbi.nlm.nih.gov/pubmed/31205508 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919849757 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|